Online inquiry

IVTScrip™ mRNA-Anti-IGF, MEDI-573(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ11373MR)

This product GTTS-WQ11373MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets IGF1&IGF2 gene. The antibody can be applied in Breast Cancer research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000618.5; NM_000612.6
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3479; 3481
UniProt ID P05019; P01344
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IGF, MEDI-573(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ11373MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ11022MR IVTScrip™ mRNA-Anti-CD3E&CLEC12A, MCLA-117(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA MCLA-117
GTTS-WQ6124MR IVTScrip™ mRNA-Anti-IL6, COR-001(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA COR-001
GTTS-WQ1429MR IVTScrip™ mRNA-Anti-Aβ15-42, ACC-001(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ACC-001
GTTS-WQ10955MR IVTScrip™ mRNA-Anti-IL17A&IL17F, MCAF-5352A(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MCAF-5352A
GTTS-WQ12366MR IVTScrip™ mRNA-Anti-EGFR, N63Ab(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA N63Ab
GTTS-WQ4431MR IVTScrip™ mRNA-Anti-CTLA4, BMS-734016(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BMS-734016
GTTS-WQ6486MR IVTScrip™ mRNA-Anti-S, CT-P-59(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA CT-P-59
GTTS-WQ1314MR IVTScrip™ mRNA-Anti-MET, ABT-700(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA ABT-700
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW